Applied Therapeutics' first development target is an enzyme called Aldose Reductase. Utilizing advanced crystallography, the company has developed a unique understanding of structural changes within the enzyme active site, which has enabled functional design of new compounds to improve binding affinity and specificity. These new compounds have higher Aldose Reductase inhibitory activity and less off-target activity.
AT-007-1005 Clinical Study
Please fill out the form below to view information about AT-007, e.g. a list of contraindicated medications.